Paper Details

  1. Home
  2. Paper Details

An Investigation of Structure-Activity Relationships of Azolylacryloyl Derivatives Yielded Potent and Long-Acting Hemoglobin Modulators for Reversing Erythrocyte Sickling.

Author: AbdulmalikOsheiza, El-ArabyMoustafa E, GhatgeMohini S, MuhammadYosra A, OmarAbdelsattar M, ParedesSteven D, SafoMartin K

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This study describes the development of novel antisickling agents that bind to sickle hemoglobin (HbS) to increase its oxygen affinity and inhibit erythrocyte sickling. These agents, designated MMA, show significantly enhanced and sustained pharmacologic activities in vitro.
Paper Details　
Original Abstract of the Article :
Aromatic aldehydes that bind to sickle hemoglobin (HbS) to increase the protein oxygen affinity and/or directly inhibit HbS polymer formation to prevent the pathological hypoxia-induced HbS polymerization and the subsequent erythrocyte sickling have for several years been studied for the treatment o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7693414/

データ提供：米国国立医学図書館（NLM）

Azolylacryloyl Derivatives: A New Hope for Sickle Cell Disease

Sickle cell disease (SCD) is a debilitating genetic disorder that affects millions worldwide. This study focuses on the development of new drugs to treat SCD. The researchers investigated the potential of a new class of compounds, azolylacryloyl derivatives, as hemoglobin modulators to prevent erythrocyte sickling. The study found that these compounds were effective in increasing hemoglobin oxygen affinity and inhibiting sickle cell polymerization, offering a promising new treatment option for SCD.

Azolylacryloyl Derivatives: A Potential Breakthrough in SCD Treatment

The study discovered that azolylacryloyl derivatives were effective in increasing hemoglobin oxygen affinity and inhibiting sickle cell polymerization, demonstrating their potential as a new treatment for SCD. These compounds showed a significantly enhanced and sustained pharmacologic activity in vitro, highlighting their potential for long-lasting therapeutic effects.

A Camel's Journey Through the Desert of SCD: A Glimpse of Hope

This research offers a beacon of hope for those living with SCD. The development of azolylacryloyl derivatives could lead to new and effective treatments, potentially improving quality of life and reducing the burden of this debilitating disease. Think of it as a camel navigating a vast desert, searching for a solution to the challenges of SCD.

Dr. Camel's Conclusion

This study presents a promising new approach for treating SCD. The discovery of azolylacryloyl derivatives as potent and long-acting hemoglobin modulators opens the door to new therapeutic options that could significantly improve the lives of patients with SCD.
Date :
  1. Date Completed 2021-06-24
  2. Date Revised 2021-06-24
Further Info :

Pubmed ID

33147875

DOI: Digital Object Identifier

PMC7693414

Related Literature

Article Analysis
・Effects of voxelotor
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.